Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures.
about
Zonisamide add-on for drug-resistant partial epilepsyZonisamide add-on for drug-resistant partial epilepsyZonisamide in the management of epilepsy in the elderlyProfile of once-daily zonisamide as monotherapy for treatment of partial seizures in adultsRole of oxidative stress in epileptic seizures.Safety and tolerability of perampanel: a review of clinical trial data.Zonisamide for drug-resistant partial epilepsy.Efficacy and tolerability of the new antiepileptic drugs, II: Treatment of refractory epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society.Zonisamide Combined with Cognitive Behavioral Therapy in Binge Eating Disorder: A One-year Follow-up Study.New generation antiepileptic drugs: what do they offer in terms of improved tolerability and safety?Zonisamide discontinuation due to psychiatric and cognitive adverse events: a case-control studyBeneficial and adverse psychotropic effects of antiepileptic drugs in patients with epilepsy: a summary of prevalence, underlying mechanisms and data limitations.Comparative efficacy and tolerability of anti-epileptic drugs for refractory focal epilepsy: systematic review and network meta-analysis reveals the need for long term comparator trialsThree new drugs for epilepsy: levetiracetam, oxcarbazepine, and zonisamide.Negative effects of antiepileptic drugs on mood in patients with epilepsy.Drug treatment of epilepsy in the century of the ILAE: the second 50 years, 1959-2009.Protective effect of melatonin against zonisamide-induced reproductive disorders in male ratsClinical experience with zonisamide monotherapy and adjunctive therapy in children with epilepsy at a tertiary care referral center.Zonisamide: newer antiepileptic agent with multiple mechanisms of action.Drug points: Weight loss associated with levetiracetam.Emerging drugs for eating disorder treatment.Zonisamide for the treatment of epilepsy.Evaluation of safety and efficacy of zonisamide in adult patients with partial, generalized, and combined seizures: an open labeled, noncomparative, observational Indian study.A long-term follow-up of zonisamide monotherapy.Refractory epilepsy: clinical overview.Weight issues for people with epilepsy--a review.Clinical perspectives on lacosamideZonisamide - a review of experience and use in partial seizures.Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature.Placebo-corrected efficacy of modern antiepileptic drugs for refractory epilepsy: systematic review and meta-analysis.Zonisamide decreases current-source density of high Beta frequency of electroencephalogram.Zonisamide in the treatment of epilepsy.Adjunctive antiepileptic drugs in adult epilepsy: how the first add-on could be the last.Factors determining response to antiepileptic drugs in randomized controlled trials. A systematic review and meta-analysis.Drug safety evaluation of zonisamide for the treatment of epilepsy.Zonisamide in the treatment of epilepsy.Review of therapeutic options for adjuvant treatment of focal seizures in epilepsy: focus on lacosamide.Placebo-corrected efficacy of modern nonenzyme-inducing AEDs for refractory focal epilepsy: systematic review and meta-analysis.Zonisamide: its pharmacology, efficacy and safety in clinical trials.Zonisamide in clinical practice.
P2860
Q24201699-56733688-F83D-4F56-839A-F7436812A0C1Q24245889-14747D79-2715-4FAC-B89F-8B46408DA148Q26820856-2631FCC4-453D-4940-988C-3B547D116D67Q26995736-C3C3CC1B-6A6B-4E80-BA87-D36F5178C654Q30456096-70F0784D-A2DA-4122-8069-C114B3D3E163Q30597533-EE21CA5C-DEE9-4384-844E-8E778552CDBCQ30868277-24F356E2-D29B-44F1-A132-E1E467CFBBFCQ33202111-CDE7AE1F-8A62-4D12-840F-39F7E0EA5DE0Q33570632-6BBF3804-5577-421A-BE0B-9F3B5C624FC2Q33949491-E84A2501-4E0D-469C-8226-637B5DE62877Q34053280-09DEE4A3-C524-4830-8B27-D8AF22AC5CBDQ34186198-AF7D31CC-D521-4231-BA76-73FC5308470EQ34563933-32317BD2-FA69-4F4F-8BFC-84F42F27DA7CQ34579452-D235A152-3822-44D8-A98C-11D65FD0BE49Q34580773-B9E06074-6E6D-47E9-9FC8-88890EEEA0DAQ34965263-EF07E70F-05F5-4287-B588-8F8073BDE1CBQ35829199-50AF5A24-454C-4386-85CB-979A59B3464CQ36099200-454459E5-2CC2-4EE3-A0EA-07CF1E6B8E61Q36106890-461EE4DB-36EF-418F-A7C3-E61540DC056DQ36351935-DF4A0F2D-CF82-4B5D-BC78-B23CD4675CFAQ36458423-CAD0F1A4-0777-41B7-8BBC-C05744B0F675Q36607320-E0F8DC4A-0907-4105-B7C5-AC98AFC22F42Q36653057-D2944268-8600-4408-855F-8DB375D82406Q36658198-1E481706-0A88-4F18-B102-CAD0EC2B6504Q36742732-171A3A34-370B-46E7-A7CC-4D2AE6EFC8F9Q37019215-B03DD39A-6CFB-47ED-8933-D7211CCA0AB4Q37156322-8A8101F4-1B84-4EB5-A1AE-E27518A20BDFQ37165710-C98A6F5C-ABFB-40A6-AC82-B09390E86E4CQ37224576-A319E2A0-444D-47F1-A1C8-71E62EE3D821Q37594857-0F15C71C-773A-48DA-8430-850B6B7ADE91Q37634545-53536AEB-FD89-495B-A26F-432596C24673Q37650321-355606F3-2451-4D92-B295-D7E4D6EFDCBBQ37733552-7C7A942C-60E0-4657-B3F1-DF0D1FB83EC5Q37832531-1774B37C-ED69-4A89-A805-71E146B97CADQ37887798-BAD95BD4-87B0-4040-9241-83A9A4D2861CQ37941836-35BF1F45-449F-4AE0-BF92-1B977D448845Q37964697-45A68FBB-B3E8-4698-8F77-82400289C560Q37975526-2D2DDBB0-2830-4F6A-9805-49AFE0AFEAADQ38056166-FEF5B4C0-755C-4F41-993C-82ACC61D764EQ38056168-5C9AAB86-CD61-456C-921B-4068CDE02FD9
P2860
Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Randomized controlled trial of ...... actory partial-onset seizures.
@en
Randomized controlled trial of ...... actory partial-onset seizures.
@nl
type
label
Randomized controlled trial of ...... actory partial-onset seizures.
@en
Randomized controlled trial of ...... actory partial-onset seizures.
@nl
prefLabel
Randomized controlled trial of ...... actory partial-onset seizures.
@en
Randomized controlled trial of ...... actory partial-onset seizures.
@nl
P2093
P356
P1433
P1476
Randomized controlled trial of ...... actory partial-onset seizures.
@en
P2093
G G Montouris
I E Leppik
Zonisamide 922 Trial Group
P304
P356
10.1212/WNL.57.10.1774
P407
P577
2001-11-01T00:00:00Z